NeuroSense Therapeutics (NRSN) vs Exicure (XCUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
NeuroSense Therapeutics is the larger company by market cap ($6.9 million vs $6.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRSN | XCUR |
|---|---|---|
| Share price | $3.66 | $1.05 |
| Market cap | $6.94M | $6.87M |
| 1-day change | -2.14% | +3.96% |
| EPS (TTM) | $-47.10 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.64 | $9.48 |
| 52-week low | $3.56 | $0.936 |
| Distance from 52-week high | -86.26% | -88.92% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +2559.29% | — |
| Average volume | 21.58K | 399.32K |
| Shares outstanding | 1.90M | 6.55M |
| Employees | 17 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About NeuroSense Therapeutics
NRSN stock →NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About Exicure
XCUR stock →Exicure, Inc. does not have significant operations.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
NRSN vs XCUR FAQ
Which is bigger, NeuroSense Therapeutics or Exicure?
NeuroSense Therapeutics (NRSN) is larger, with a market capitalization of $6.94M compared with $6.87M for Exicure (XCUR).
Are NeuroSense Therapeutics and Exicure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.